Hemisynthetic Method and New Compounds
    4.
    发明申请
    Hemisynthetic Method and New Compounds 有权
    半合成方法和新化合物

    公开(公告)号:US20080045713A1

    公开(公告)日:2008-02-21

    申请号:US11774890

    申请日:2007-07-09

    IPC分类号: C07D471/08 C07D491/147

    摘要: Methods are provided for preparing a compound with a fused ring structure of formula (XIV) which comprises one or more reactions starting from a 21-cyano compound of formula (XVI) where typically; R1 is an amidomethylene group or an aryloxymethylene group; R5 and R8 are independently chosen from —H, —OH or —OCOCH2OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring; R14a and R14b are both —H ozone is —H and the other is —OH, —OCH3 or —OCH2CH3, or R14a and R14b together form a keto group; and R15 and R18 are independently chosen from —H or —OH, or R5 and R8 are both keto and the ring A is a p-benzoquinone ring. In modified starting materials, the 21-cyano group can be replaced by other groups introduced using nucleophilic reagents.

    摘要翻译: 提供了制备具有式(XIV)的稠环结构的化合物的方法,其包含一个或多个由式(XVI)的21-氰基化合物开始的反应,其中通常; R 1是酰亚胺基或芳氧基亚甲基; R 5和R 8独立地选自-H,-OH或-OCOCH 2 OH,或R 5 O >和R 8均为酮,环A为对苯醌环; R 14a和R 14b都是-H臭氧是-H,另一个是-OH,-OCH 3或-OCH 3 2 3,或R 14a和R 14b共同形成酮基; R 15和R 18独立地选自-H或-OH,或R 5和R 8, 都是酮基,环A是对苯醌环。 在改性原料中,21-氰基可以被其它使用亲核试剂引入的基团所取代。

    Ecteinascidin analogs for use as antitumour agents
    7.
    发明授权
    Ecteinascidin analogs for use as antitumour agents 有权
    用作抗肿瘤剂的抗坏血酸类抗生素

    公开(公告)号:US07763615B2

    公开(公告)日:2010-07-27

    申请号:US10485536

    申请日:2002-08-06

    CPC分类号: C07D515/22

    摘要: Derivatives of ecteinascidin 736 of general formula (I) wherein the groups R1, R2, R3, R4 and R5 are each independently selected from the group consisting of H, OH, OR′, SH, SR′, SOR′, SO2R′, C(═O)R′, C(═O)OR′, NO2, NH2, NHR′, N(R′)2, NHC(O)R′, CN, halogen, ═O, substituted or unsubstituted C1-C25 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heterocyclic; wherein X is independently selected of OR′, CN, (═O), or H; wherein each of the R′ groups is independently selected from the group consisting of H, OH, NO2, NH2, SH, CN, halogen, ═O, C(═O)H, C(═O)CH3, CO2H, substituted or unsubstituted C1-C25 alkyl, substituted or unsubstituted C2-C18 alkenyl, substituted or unsubstituted C2-C18 alkynyl, substituted or unsubstituted aryl; wherein m is 0, 1 or 2; and wherein n is 0, 1, 2, 3, or 4, and their use as antitumoral agent.

    摘要翻译: 基团R 1,R 2,R 3,R 4和R 5各自独立地选自H,OH,OR',SH,SR',SOR',SO 2 R',C的通式(I)的抗坏血酸素736衍生物 (= O)R',C(= O)OR',NO 2,NH 2,NHR',N(R')2,NHC(O)R',CN,卤素,= O,取代或未取代的C 1 -C 25烷基 取代或未取代的C 2 -C 18烯基,取代或未取代的C 2 -C 18炔基,取代或未取代的芳基,取代或未取代的杂环基; 其中X独立地选自OR',CN,(= O)或H; 其中每个R'基团独立地选自H,OH,NO 2,NH 2,SH,CN,卤素,= O,C(= O)H,C(= O)CH 3,CO 2 H, 未取代的C 1 -C 25烷基,取代或未取代的C 2 -C 18烯基,取代或未取代的C 2 -C 18炔基,取代或未取代的芳基; 其中m为0,1或2; 并且其中n为0,1,2,3或4,并且其用作抗肿瘤剂。